ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)

[1]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG) , 2021, Genetics in Medicine.

[2]  W. Foulkes,et al.  Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) , 2021, Genetics in Medicine.

[3]  Stephen W. Hartley,et al.  Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study. , 2021, JNCI cancer spectrum.

[4]  Bahareh Behroozi Asl,et al.  Review and Consensus on Pharmacogenomic Testing in Psychiatry , 2020, Pharmacopsychiatry.

[5]  Liang‐Kung Chen,et al.  Hereditary hemorrhagic telangiectasia. , 2020, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.

[6]  K. Sangkuhl,et al.  A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy , 2020, Clinical pharmacology and therapeutics.

[7]  W. Hauswirth,et al.  Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Julie O. Culver,et al.  Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. R. Ponomareva,et al.  Pompe disease , 2018, Meditsinskaya sestra.

[10]  Robert C. Green,et al.  Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. , 2019, American journal of human genetics.

[11]  C. Perret,et al.  FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype‐phenotype correlations , 2019, Clinical genetics.

[12]  Brandon K. Fornwalt,et al.  Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. , 2019, Circulation.

[13]  Sephalie Y. Patel,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes , 2019, Clinical pharmacology and therapeutics.

[14]  Elvira N. Chegarnov,et al.  Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy. , 2018, Human gene therapy.

[15]  Bruce E. Bowdish,et al.  Foundation of the Newborn Screening Translational Research Network and its tools for research , 2018, Genetics in Medicine.

[16]  M. Goumans,et al.  Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia , 2018, International journal of molecular sciences.

[17]  S. Richard,et al.  Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations , 2018, European Journal of Human Genetics.

[18]  R. Naylor,et al.  Maturity-Onset Diabetes of the Young Overview , 2018 .

[19]  S. Kirmani,et al.  Hereditary paraganglioma-pheochromocytoma syndrome , 2018, Medicina Clínica (English Edition).

[20]  William J. Bryant,et al.  2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.

[21]  William J. Bryant,et al.  2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.

[22]  C. Larsson,et al.  Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention , 2017, JAMA oncology.

[23]  L. Gurrin,et al.  Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes , 2017, Genetics in Medicine.

[24]  G. García-Rivas,et al.  A systematic review of genetic mutations in pulmonary arterial hypertension , 2017, BMC Medical Genetics.

[25]  L. Calò,et al.  Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. , 2016, Journal of the American College of Cardiology.

[26]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[27]  S. Packman,et al.  Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease , 2015, Journal of Medical Genetics.

[28]  B. Wolf,et al.  Biotinidase deficiency. , 2015, Indian pediatrics.

[29]  Brendan D. O'Fallon,et al.  BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. , 2013, American journal of human genetics.

[30]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[31]  D. Tregouet,et al.  Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. , 2010, American journal of respiratory and critical care medicine.

[32]  L. Mestroni,et al.  Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. , 2009, Journal of cardiac failure.

[33]  J. Oliveira,et al.  Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. , 2008, Molecular genetics and metabolism.

[34]  M. Jadoul,et al.  Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. , 2005, Diabetes.

[35]  A. Guttmacher,et al.  Hereditary hemorrhagic telangiectasia. , 1995, The New England journal of medicine.

[36]  H. Moser,et al.  X-linked adrenoleukodystrophy , 1993, Clinical Neurology and Neurosurgery.

[37]  M. Michaelides,et al.  Leber Congenital Amaurosis/Early-Onset Severe Retinal Dystrophy , 2022, Inherited Retinal Disease.

[38]  Andrew C. R. Martin,et al.  Human Mutation , 2020 .

[39]  D. Judge,et al.  Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. , 2018, Journal of cardiac failure.

[40]  William J. Bryant,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.

[41]  Newborn screening: toward a uniform screening panel and system. , 2006, Genetics in medicine : official journal of the American College of Medical Genetics.

[42]  Daniel L. Chao,et al.  Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy Overview , 1993 .

[43]  L. Fishbein,et al.  Hereditary Paraganglioma-Pheochromocytoma Syndromes , 1993 .